ArticleRMD open2026
Colchicine enhances macrophage cholesterol efflux by targeting DTL-mediated ubiquitination and degradation of ABCA1.
Article in RMD open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aims to elucidate the potential pharmacological mechanisms by which colchicine confers clinical benefits in patients with atherosclerotic cardiovascular disease, focusing on its effects on cholesterol efflux.
methodsThis study was conducted in multiple cellular models. First, cell viability was assessed and the optimal dosage of colchicine was screened via the Cell Counting Kit-8 assay. Subsequently, Oil Red O staining, commercial kit detection and Boron dipyrromethene (BODIPY) -cholesterol labelling were employed to analyse intracellular lipid accumulation, foam cell formation and cholesterol efflux rate in macrophages, respectively. Furthermore, molecular docking and transcriptome sequencing were performed to explore the potential therapeutic targets and underlying mechanisms of colchicine, followed by a series of cellular experiments (quantitative reverse transcription-PCR, ATP-binding cassette transporter A1 (ABCA1) degradation analysis, plasmid construction and transfection, co-immunoprecipitation, immunoblotting) for comprehensive validation of the identified potential mechanisms.
resultsIn the present study, we demonstrate that colchicine markedly promotes cholesterol efflux, a key process that reverses macrophage foam cell formation and consequently contributes to its cardioprotective effects. We identified modulation of the ubiquitination of ABCA1 as the pivotal mechanism by which colchicine enhances cholesterol efflux. Our findings reveal for the first time that denticleless E3 ubiquitin protein ligase homologue (DTL) functions as a crucial E3 ligase in this regulatory pathway. Mechanistically, colchicine suppresses DTL expression and disrupts its interaction with ABCA1, leading to increased ABCA1 protein stability, enhanced ABCA1-mediated cholesterol efflux and a subsequent reduction in foam cell formation.
conclusionColchicine shows great promise for drug repurposing as a novel therapeutic agent. Its strong capacity to reverse foam cell formation highlights its potential to extend clinical use beyond gout management to cardiovascular secondary prevention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.